麗珠醫藥(01513.HK)建議採納第二期持股計劃及管理辦法
格隆匯4月26日丨麗珠醫藥(01513.HK)發佈公吿,2022年4月11日,董事會建議採納第二期持股計劃及管理辦法。第二期持股計劃及管理辦法須待股東於年度股東大會通過特別決議案批准後,方可作實。第二期持股計劃遵循本公司自主決定、員工自願參加的原則,不存在攤派、強行分配等強制員工參加第二期持股計劃的情形。第二期持股計劃的資金總額為人民幣6,496.5470萬元,全部為公司計提的專項基金。
董事會認為,第二期持股計劃有利於優化薪酬結構,並依據公司業績達成情況,計提專項基金,購入公司股票,並進行中長期鎖定,有利於實現公司核心管理團隊的長期激勵與約束,確保公司長期經營目標的實現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.